Question-and-Answer Session
Operator
Thank you ladies and gentlemen. (Operator Instructions) Our first question comes from the line of Ren Benjamin with Rodman and Renshaw. Please proceed with your question.
Ren Benjamin
Hi, good morning guys, and thanks for taking the question. I guess, I have just one main one and that is, what are milestones for 2008 that we can expect from Aastrom? It seems like all the Phase III trials are ongoing, we probably won’t see anything from those trials and what’s the interim analyses planned until 2009 or so. So, can you tell us what sort of drivers are in place for 2008? What consensus we may see from that act and what additional trials will be initiated in 2008? Thank you.
George Dunbar
Sure, Ren. This is George. I think if you look at our website and the public presentations that we are giving on milestones, what we started doing last year was to layout what we saw as the significant milestones over the next 12 to 24 months. And then each time we report either at a meeting, at a conference, or on calls like this disclose and tell you where we are.
I think the current update is that we’ve achieved 6 or 7 milestones during the ?07 period, we have a similar number going forward for the 2008 time period for example in the bone regeneration area, one of the milestones we have for ?08 is to complete the 10 pension enrollment for the osteonecrosis clinical trials in Spain. We are going to review the interim osteonecrosis data -- patient data in the US in 2008 or when we get to critical mass and patients were trying to identify to be able to do that. The RESTORE-CLI trial, the Interim data 12 months after the 30th patient treatment we’re not giving guidance on exactly when that will be but you’ll hear more as we get closer to the time.
In cardiac, we announced, as you know, the treatment of the first patient because that was a milestone that we had indicated that we did we were going to achieve and we will continue to report the interim data 6 months or so after a number of patients have been treated. So you will end and this is going to be the submission of the US IND and the submission as Elmar had indicated of the INPD in Europe for Phase I/II clinical trials in ?08.
- To read the full transcript on Seeking Alpha, click here »
